Can Vaccines Be Delivered via the Lungs Instead of by Injection?

Can Vaccines Be Delivered via the Lungs Instead of by Injection?

15 October 2012 Mary Ann Liebert, Inc., Publishers

New Rochelle, NY, October 15, 2012—In addition to the obvious benefit of eliminating the need for an injection, new vaccine delivery methods via the lungs offer particular advantages for protecting against infectious agents that enter the body through the respiratory track. A comprehensive review article that presents the current status, challenges, and opportunities of pulmonary vaccine delivery is published in Journal of Aerosol Medicine and Pulmonary Drug Delivery (http://www.liebertpub.com/jamp), a peer-reviewed journal from Mary Ann Liebert, Inc., publishers (http://www.liebertpub.com). The article is available free online on the Journal of Aerosol Medicine and Pulmonary Drug Delivery (http://www.liebertpub.com/jamp) website.

In "Pulmonary Vaccine Delivery: A Realistic Approach? (http://online.liebertpub.com/doi/full/10.1089/jamp.2011.0931)" Wouter Tonnis and coauthors from University of Groningen and National Institute for Public Health and the Environment (Bilthoven), The Netherlands, describe the unique physiology and immune responsiveness of the respiratory track that make pulmonary vaccine delivery such an attractive alternative to traditional injections. Although pulmonary vaccination is still a young field, with much more research needed, evidence suggests administration of a vaccine to the lungs can induce a local immune response more effectively than conventional types of vaccine delivery, in addition to stimulating antibody production throughout the body. This could be especially important for combating pathogens that cause pulmonary diseases.

"The lung is an immunologic powerhouse that remains largely unexplored. Theoretically we should be able to avoid needles and simply inhale our vaccines," says Editor-in-Chief Gerald C. Smaldone, MD, PhD, Professor and Chief, Division of Pulmonary and Critical Care Medicine at SUNY-Stony Brook.

Webinar

Using AI and RWD to Uncover Rare Disease Insights, Accelerate Commercialization and Improve Patient Outcomes

Wednesday, March 24 | 2pm ET / 11am PT

Learn how IPM.ai transformed real world data into real world insights to assist Audentes in their development of AT132 for the treatment of XLMTM. The session reviews how IPM.ia and Audentes collaborated to uncover the XLMTM patient population.